- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02754375
SMTr-METAB : FDG-PET Assessment of Cerebral Metabolism in Resistant Depression Treated With rTMS (SMTr-METAB)
Cerebral Functional Modifications After Low Frequency Repetitive Transcranial Magnetic Stimulation in Refractory Depression. Assessment With 18F-FDG-PET Imaging.
Przegląd badań
Szczegółowy opis
In France, lifetime prevalence of depression is 21 %, with major consequences: handicap, loss of productivity, reduction in quality of life, increased mortality. The efficient and long-lasting care of depression is consequently a priority of public health.
Despite well-conducted conventional therapeutic strategies, it is estimated that about 30 % of the depressed patients do not respond at all to an antidepressant, that 30 % will present a partial response, and that 40 % only patients will have a complete remission.
Non-pharmacological alternative treatments have been promoted, particularly with repetitive transcranial magnetic stimulation (rTMS). A recent meta-analysis with 29 randomized controlled trials versus placebo reports a 29.3 % response rate and a 18.6 % remission rate after active stimulation vs respectively, 10.4 % and 5 % after placebo stimulation.
However, predictive biomarkers of response are unknown, and cerebral metabolism may be a good candidate. It is admitted that the depressive state is correlated with specific modifications of glucose metabolism in circuits which are involved in the neurobiology of depression. The amplitude of these changes may correlate with clinical severity or may differ with treatment type, and cerebral metabolic changes might be an additional guide to treatment. Finally, the therapeutic effect might normalize cerebral functional activity and this might be an early correlate of clinical response. However the studies using functional imaging in a therapeutic approach or in the understanding of the physiopathology of the depression are not usable in a clinical practice of routine.
The investigators suggest using a well-known analysis software (Scenium software, Siemens GmbH) who allows an automated analysis by the distribution of the cerebral metabolism by means of the F18-FDG TEP-TDM and a quantitative measure, expressed in regional consumption of glucose expressed by g / 100 g / min for every 18F-FDG TEP-TDM and for every region of interest. Image registering by the camera, remote of the injection of the tracer, lasts less than 10 minutes.The software also allows to compare the data acquired for a patient with a standardized database.
The investigators will perform a opened study in two centers (Monaco Hospital/Nice CHU) on 50 depressed patients aged from 40 to 65 years old, not having answered 2 lines of well led antidepressants. Low-frequency rTMS will be proposed in acute cure (3 in 6 weeks) in monotherapy followed by 6 months of rTMS for patients who have responded to acute treatment phase.
Cerebral metabolic modifications (location and intensity) will be calculated after two PET-TDM in every patient, realized before and after the acute treatment by rTMS. We shall use the SCENIUM software which allows to compare each patient's data with a standardized database.
At the end of the acute period of treatment, it will be proposed to patients who have responded to pursue rTMS treatment in a consolidation phase for 6 months. All patients will be longitudinally assessed during this consolidation period. One objective is to assess if initial TEP-TDM data and/or the amplitude of the induced metabolic variation is associated with the stability of the clinical answer in respondent patients
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Subject from 40 to 65 years old
- Characterized current depressive Episode, unipolar, without psychotic characteristic (according to DSM IV-TR)
- Presenting to the inclusion a score upper or equal to 20 on the scale HDRS-17
- Absence of answer or partial clinical answer to more than two antidepressant treatments of different therapeutic classes to effective posology on a duration of at least 6 weeks
- Patient affiliated to French social security
- Patient must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed study consent according to local laws and regulations
Exclusion Criteria:
- Failure in a previous low-frequency rTMS cure (at least 15 sessions)
- Failure in a cure of bilateral ECT (at least 8 sessions) or unilateral (at least 10 sessions)
- Mental disorder owed to a general medical affection ( DSM-IV)
- Presence of a neurodegenerative pathology in the inclusion estimated on the clinical examination, the intellectual MRI, the TEP / TDM at the 18F-FDG and the neuropsychological profile in the inclusion
- Severe or not stabilized somatic Disease
- chronic depression evolving for more than 3 years
- Not answer in more of therapeutic antidepressive five well (documented) conducts
- Presence of contraindication the SMTr, of which epileptic disease
- Schizophrenic Disorder
- Addicting Disorder with current dependence (alcohol, cannabis, benzodiazepin)
- Bipolar disorder (I, II)
- Disorder of personality to cluster A and B co-morbid
- Pregnant Woman (dosage of urinary Beta-HCG)
- Vulnerable Person: major under guardianship or guardianship, minor
- Mental Deficiency of the subject making its participation on approval impossible
- Participation in another clinical trial
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Patient
Patient with resistant depression treated with rTMS
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Variation of the regional cerebral glucose consumption between the two PET-TDM
Ramy czasowe: at week 6
|
Variation of the regional cerebral glucose consumption between the two PET-TDM (realized at inclusion and at Week 6)
|
at week 6
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Comparison of local glucose use between responder and non-responder patients
Ramy czasowe: at week 6
|
at week 6
|
Współpracownicy i badacze
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 15-PP-02
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na rTMS
-
Chang Gung Memorial HospitalRekrutacyjny
-
Changping LaboratoryBeijing HuiLongGuan HospitalRekrutacyjnyCiężkie zaburzenie depresyjne | Ciężka depresja | Umiarkowana depresjaChiny
-
Centre hospitalier de Ville-Evrard, FranceRekrutacyjnyOcena skuteczności Open rTMSFrancja
-
National Taiwan University Hospital Hsin-Chu BranchJeszcze nie rekrutacja
-
Bayside HealthZakończonyZaburzenie autystyczne | Zespół AspergeraAustralia
-
Changping LaboratoryWuhan Mental Health CentreRekrutacyjnyCiężkie zaburzenie depresyjne | Ciężka depresja | Umiarkowana depresjaChiny
-
Prof. Dominique de Quervain, MDRekrutacyjnyPamięć, epizodycznySzwajcaria
-
The Cleveland ClinicAmerican Heart AssociationZakończony
-
Centre Hospitalier Universitaire de Saint EtienneZakończonyBól neuropatycznyFrancja
-
Butler HospitalZakończonyModulowanie obwodów przedczołowych leżących u podstaw elastyczności behawioralnej w OCD: badanie TMSNerwica natręctwStany Zjednoczone